Domov › Akutna mieločna levkemija › Maryland › Baltimore
Klinične študije za Akutna mieločna levkemija v Baltimore, MD
19 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Baltimore in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Mercy Medical Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore
- in še 2
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Vključevanje udeležencevFaza 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Vključevanje udeležencevFaza 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Vključevanje udeležencevZgodnja faza 1
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Vključevanje udeležencevFaza 2
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Vključevanje udeležencevFaza 1/2
- Johns Hopkins University, Baltimore
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Vključevanje udeležencevFaza 3
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Vključevanje udeležencevFaza 2
- John Hopkins School of Medicine, Baltimore
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Vključevanje udeležencevFaza 3
- US-Baltimore MD-UMGCCC, Baltimore
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Vključevanje udeležencevFaza 3
- US-Baltimore MD-UMGCCC, Baltimore
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Vključevanje udeležencevFaza 1
- University of Maryland/Greenebaum Cancer Center, Baltimore
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Vključevanje udeležencevFaza 1/2
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies
Vključevanje udeležencevFaza 1
- Tania Jain, MD, Baltimore
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Vključevanje udeležencevFaza 3
- University of Maryland Medical Center (UMMC), Baltimore
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Vključevanje udeležencevOpazovalna študija
- Johns Hopkins, Baltimore
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Vključevanje udeležencevFaza 2
- University of Maryland Greenebaumn Comprehensive Cancer Center, Baltimore
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Vključevanje udeležencevFaza 1/2
- Sibley Memorial Hospital, Baltimore
- University of Maryland, Baltimore
- Johns Hopkins Main Center, Baltimore
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Vključevanje udeležencevFaza 1
- Johns Hopkins School of Medicine, Baltimore
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Vključevanje udeležencevVabljeni zdravi prostovoljci
- Johns Hopkins University, Baltimore
Študije za Akutna mieločna levkemija v drugih mestih
- Houston, TX85 študij
- New York City, NY51 študij
- Boston, MA44 študij
- Baldwin Park, CA40 študij
- Seattle, WA40 študij
- Columbus, OH35 študij
- Philadelphia, PA34 študij
- Durham, NC33 študij
- Atlanta, GA30 študij
- Tampa, FL29 študij
- Chicago, IL26 študij
- Portland, OR25 študij
Druge študije v Baltimore
- Nemalicelični pljučni rak60 študij
- Rak dojke47 študij
- Rak prostate43 študij
- Rak pljuč40 študij
- Rak (vse vrste)37 študij
- Kolorektalni rak31 študij
- Rak trebušne slinavke31 študij
- Metastatski rak28 študij
- Debelost25 študij
- Srčno popuščanje24 študij
- Rak mehurja24 študij
- Možganska kap22 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.